SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Has Filed a Class Action Lawsuit Against Intercept

  SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Has
  Filed a Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and
  Certain Officers

Business Wire

SAN DIEGO -- February 22, 2014

Shareholder rights law firm Johnson & Weaver, LLP announced today that it
filed a class action lawsuit in the United States District Court for the
Southern District of New York on behalf of purchasers of Intercept
Pharmaceuticals, Inc. (“Intercept” or the “Company) (NASDAQ: ICPT) publicly
traded securities between January 9, 2014 and January 10, 2014, inclusive (the
“Class Period”). This complaint alleges that Intercept and certain of its
officers violated the Securities Exchange Act of 1934. Intercept is a
pharmaceutical company headquartered in New York, New York and focuses on
liver disease treatments.

The Complaint alleges that throughout the Class Period, Defendants made false
and/or misleading statements, as well as failed to disclose material adverse
facts. Specifically, before the stock market opened on January 9, 2014,
Intercept announced that the FLINT clinical trial study of obeticholic acid
(OCA) was stopped early for efficacy after a planned interim analysis showed
the primary endpoint had been met. OCA is being developed by Intercept for the
treatment of nonalcoholic steatohepatitis. On this news announcement, shares
of Intercept Pharmaceuticals increased over 500% over the next two trading
sessions.

After the market close on Friday, January 10, 2014, The Wall Street Journal
issued a report via a statement made by the National Institutes of Health
stating that patients treated with Intercept's OCA in the clinical trial
experienced "lipid abnormalities", higher levels of "bad" LDL cholesterol and
lowers levels of "good" HDL cholesterol, compared to patients treated with
placebo. By Tuesday, January 14, 2014, the stock traded down as much as $210
or 47%.

Plaintiff seeks to recover damages on behalf of all purchasers of Intercept
publicly traded securities during the Class Period (the “Class”).

If you wish to serve as a lead plaintiff, you must move the Court no later
than 60 days from today.

If you wish to discuss this action, have any questions concerning this notice,
or your rights or interests, please contact lead analyst Jim Baker
(jimb@johnsonandweaver.com) at 619-230-0063. More information concerning this
action is also available at www.johnsonandweaver.com. Any member of the
putative class may move the Court to serve as lead plaintiff through counsel
of their choice, or may choose to do nothing and remain an absent class
member.

Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law firm
with offices in New York, New York and San Diego, California. The firm
represents individual and institutional investors in shareholder derivative
and securities class action lawsuits. For more information about the firm and
its attorneys, please visithttp://www.johnsonandweaver.com.

Contact:

Johnson & Weaver, LLP
Jim Baker, 619-230-0063, Ext. 118
jimb@johnsonandweaver.com
 
Press spacebar to pause and continue. Press esc to stop.